$SCYYF

2024 Q3 Form 10-Q Financial Statement

#000143774924026676 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $114.2K
YoY Change 6.93%
% of Gross Profit
Research & Development $22.15K
YoY Change -84.61%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $90.54K $136.3K
YoY Change -32.81% -45.62%
Operating Profit
YoY Change
Interest Expense $132.1K
YoY Change 9.22%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.260K
YoY Change -96.72%
Income Tax
% Of Pretax Income
Net Earnings -$79.62K -$4.257K
YoY Change -206.54% -96.72%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 355.9M 355.9M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $800.5K
YoY Change -41.17%
Cash & Equivalents $718.5K $800.5K
Short-Term Investments
Other Short-Term Assets $20.43K
YoY Change -44.95%
Inventory
Prepaid Expenses $13.45K $20.43K
Receivables
Other Receivables
Total Short-Term Assets $731.9K $821.0K
YoY Change -36.67% -41.27%
LONG-TERM ASSETS
Property, Plant & Equipment $704.1K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.71K
YoY Change -1.65%
Other Assets
YoY Change
Total Long-Term Assets $715.2K $714.8K
YoY Change 0.08% -0.03%
TOTAL ASSETS
Total Short-Term Assets $731.9K $821.0K
Total Long-Term Assets $715.2K $714.8K
Total Assets $1.447M $1.536M
YoY Change -22.63% -27.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $64.95K
YoY Change -63.37%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $263.2K
YoY Change -69.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $263.2K
Total Long-Term Liabilities $0.00
Total Liabilities $254.2K $263.2K
YoY Change -52.62% -69.57%
SHAREHOLDERS EQUITY
Retained Earnings -$115.1M -$115.1M
YoY Change 0.32% 0.19%
Common Stock $111.1M $111.1M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.193M $1.273M
YoY Change
Total Liabilities & Shareholders Equity $1.447M $1.536M
YoY Change -22.63% -27.32%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$79.62K -$4.257K
YoY Change -206.54% -96.72%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$107.8K
YoY Change -41.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -107.8K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -107.8K
YoY Change -41.53%
FREE CASH FLOW
Cash From Operating Activities -$107.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
106244 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
59945 usd
CY2024Q2 us-gaap Liabilities
Liabilities
263172 usd
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
111144603 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1033333
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1264194 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7306631 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-853400 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115061095 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1272545 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1535717 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
355860813
us-gaap Net Income Loss
NetIncomeLoss
-155453 usd
us-gaap Share Based Compensation
ShareBasedCompensation
48633 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
111144603 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1033333
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1264194 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7306631 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-853400 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114905642 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1427998 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1777257 usd
CY2023Q2 scy Exploration Expense Recovery
ExplorationExpenseRecovery
143902 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28087 usd
CY2024Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
130000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001408146
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2024Q2 scy Common Stock Votes Per Share
CommonStockVotesPerShare
1 pure
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
355860813
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
355860813
CY2024Q2 scy Exploration Expense Recovery
ExplorationExpenseRecovery
22152 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16536 usd
CY2024Q2 us-gaap General Insurance Expense
GeneralInsuranceExpense
7834 usd
CY2023Q2 us-gaap General Insurance Expense
GeneralInsuranceExpense
7850 usd
CY2024Q2 us-gaap Professional Fees
ProfessionalFees
47040 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
19217 usd
CY2024Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
30811 usd
CY2023Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
63166 usd
CY2024Q2 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
398 usd
CY2023Q2 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
0 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
136322 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
250671 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5289 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9256 usd
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
7354 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
10353 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
119818 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4257 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-129756 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
355860813
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
76932 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
549624 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
7891 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-41957 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19783 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3567 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-939 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-135539 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-221432 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-491896 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-221432 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-491896 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1021956 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1852710 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
800524 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1360814 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1093279 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26949 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
236000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1356228 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21684 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-129756 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1248156 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10906 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
74732 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1333794 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
227976 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-133772 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1427998 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-151196 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1276802 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4257 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1272545 usd
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NATURE AND CONTINUANCE OF OPERATIONS</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">Scandium International Mining Corp. (“The Company”) is a specialty metals and alloys company focusing on scandium and other specialty metals.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">The Company was incorporated under the laws of the Province of British Columbia, Canada in 2006. The Company currently trades on the Toronto Stock Exchange under the symbol “SCY”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">The Company’s focus is on the exploration and evaluation of its specialty metals assets, specifically the Nyngan scandium deposit located in New South Wales, Australia. The Company is an exploration stage company and anticipates incurring significant additional expenditures prior to production at any and all of its properties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">These condensed interim consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities at their carrying values in the normal course of business for the foreseeable future. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">The Company currently earns no operating revenues and will require additional capital in order to advance the Nyngan property. The Company’s ability to continue as a going concern is uncertain and is dependent upon the generation of profits from mineral properties, obtaining additional financing and maintaining continued support from its shareholders and creditors. These are material uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern. In the event that additional financial support is not received, or operating profits are not generated, the carrying values of the Company’s assets may be adversely affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">The political upheavals in various countries have caused significant volatility in commodity prices. While these effects are expected to be temporary, the duration of the business disruptions internationally and related financial impact cannot be reasonably estimated at this time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;"><b>Use of estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">The preparation of unaudited condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuations, asset impairment, stock-based compensation, derivative liabilities and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">The Company considers itself to be an exploration stage company and will consider the transition to development stage after it receives funding to begin mine construction, and board approval.</p>
CY2024Q2 us-gaap Mineral Properties Gross
MineralPropertiesGross
704053 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34665000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.14
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
11400000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.035
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
6050000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.22
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
40015000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3290000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.15
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
36725000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.091
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
36725000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.091
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
36725000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
36725000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48633 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1033333
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1264194 usd
CY2024Q2 us-gaap Mineral Rights
MineralRights
704053 usd
CY2024Q2 scy Property Plant And Equipment Net Including Mineral Rights Total
PropertyPlantAndEquipmentNetIncludingMineralRightsTotal
704053 usd
CY2023Q4 us-gaap Mineral Rights
MineralRights
704053 usd
CY2023Q4 scy Property Plant And Equipment Net Including Mineral Rights Total
PropertyPlantAndEquipmentNetIncludingMineralRightsTotal
704053 usd

Files In Submission

Name View Source Status
0001437749-24-026676-index-headers.html Edgar Link pending
0001437749-24-026676-index.html Edgar Link pending
0001437749-24-026676.txt Edgar Link pending
0001437749-24-026676-xbrl.zip Edgar Link pending
ex_710061.htm Edgar Link pending
ex_710062.htm Edgar Link pending
ex_710063.htm Edgar Link pending
ex_710064.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
graph01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nsw01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scandium01.jpg Edgar Link pending
scy-20240630.xsd Edgar Link pending
scy20240630_10q.htm Edgar Link pending
Show.js Edgar Link pending
scy-20240630_cal.xml Edgar Link unprocessable
scy-20240630_def.xml Edgar Link unprocessable
scy-20240630_lab.xml Edgar Link unprocessable
scy-20240630_pre.xml Edgar Link unprocessable
scy20240630_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable